SCYNEXIS, Inc. today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International Conference at the Boston Convention and Exhibition Center on Wednesday, June 6, 2018 from 4:15 - 5:15 p.m. ET.
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International Conference at the Boston Convention and Exhibition Center on Wednesday, June 6, 2018 from 4:15 - 5:15 p.m. ET. The panel, titled “Fueling Antifungus Among Us: The Cost to Keep Up,” will explore strategies to fund the development of antifungal treatments. Panel participants will include representatives from the private and public equity communities and fellow antifungal treatment developers.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company’s lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
CONTACT:
Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-a-panel-at-the-2018-bio-international-convention-300652176.html
SOURCE SCYNEXIS, Inc.
